Comparative Bioavailability Study of Lisinopril Tablets, 10 mg

This study has been completed.
Sponsor:
Collaborator:
PharmaKinetics Laboratories, Inc.
Information provided by:
Par Pharmaceutical, Inc.
ClinicalTrials.gov Identifier:
NCT01375244
First received: April 1, 2008
Last updated: June 16, 2011
Last verified: April 2008

April 1, 2008
June 16, 2011
June 1999
October 1999   (final data collection date for primary outcome measure)
Rate and extent of absorption [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01375244 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparative Bioavailability Study of Lisinopril Tablets, 10 mg
Randomized, Open-label, Two-treatment Crossover, of a 10 mg Single Oral Dose, Study to Compare the Lisinopril Plasma Levels Produced After Administration of the Test Formulation With Those Produced After Administration of a Marketed Reference Product, Zestril(R), Under Fasting Conditions.

The purpose of this study is to compare the bioavailability of Par Lisinopril 10 mg Tablets and IPR Pharmaceuticals, Inc. Zestril (R).

To compare the bioavailability of Par and IPR (Zestril(R)), Lisinopril 10 mg Tablets under fasting conditions.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: Lisinopril
    Tablets, 10 mg, single dose
    Other Name: Zestril
  • Drug: Zestril
    Tablets, 10 mg, single dose
    Other Name: lisinopril
  • Experimental: A
    Subjects received the Par formulated product.
    Intervention: Drug: Lisinopril
  • Active Comparator: B
    Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
    Intervention: Drug: Zestril
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
October 1999
October 1999   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males, healthy, 18-50 years of age,
  • No more than plus or minus 15% from ideal weight for subject's height as defined by Metropolitan Life Insurance Company Statistical Bulletin 1983,
  • Without a history of asthma, angioedema, hypertension, psychiatric illness, organ-system (cardiovascular, neurological, hematopoietic, renal, pulmonary, endocrine, or gastrointestinal,) disorders, ongoing infectious diseases, alcohol or drug abuse as determined by a medical history and/or physical examination within 30 days prior to the start of the study. Deviations may be acceptable if deemed not clinically significant by the investigator.
  • Blood chemistry (including alkaline phosphatase, glucose, ALt, AST, LDH, BUN, GGT, creatinine, bilirubin, electrolytes), hematology (including hemoglobin, hematocrit, red blood cell count, white blood cell count, differential, platelet count), and urinalysis values within clinically acceptable limits upon evaluation by the investigator. The above tests will be performed within 30 days prior to the start of the study.
  • No prescription drugs within 14 days, or OTC preparations (with the exception of acetaminophen, vitamins, medicated lozenges, dietary supplements and topical medications) within 7 days of the first drug administration, each period. Deviations may be acceptable if evaluated by the investigator and determined not to be clinically significant.
  • No alcohol consumption for at least 48 hours prior to drug administration until after the last blood collection, each period.
  • No known allergy to lisinopril or other ACE (angiotensin converting enzyme) inhibitors, such as captopril and enalapril, or to atropine.
  • Acceptable electrocardiogram: sinus rhythm with no evidence of AV block or ischemic changes.
  • At screening and check-in for each period, subjects must have blood pressure and pulse rate within the following ranges: Systolic blood pressure (110-150 mmHg); Diastolic blood pressure (70-95 mmHg); Pulse (50-105 bpm). Minor deviations (1-3 mmHg) at check-in may be acceptable at the discretion of the physician investigator. For all except the first period check-in, if a subject's vital signs measurements fall outside the range specified above, the subject may, at the discretion of the physician investigator, be allowed to remain enrolled until 0-hour measurements are made. If the 0-hour protocol vital signs requirements are met, the investigator may allow dosing and the subject's continuation in the study. If 0-hour vital signs requirements are not met, the subject will not be dosed and must be withdrawn from the study. The blood pressure and pulse will be measured after the subject has been seated at least three minutes. Subjects with blood pressure and pulse measurements outside the ranges will have their vital signs measurements repeated according to Standard Operating Procedure.
  • No caffeine for at least 48 hours prior to dosing until after the last blood collection, each period.
  • Negative HIV 1, hepatitis B surface antigen and urine screen for drugs of abuse within 30 days prior to the start of the study.

Exclusion Criteria:

  • All Females, and males younger than 18 years of age or older than 50 years of age are not eligible to participate in this study.
  • A weight that is more than plus or minus 15% from ideal weight for subject's height as defined by Metropolitan Life Insurance Company Statistical Bulletin 1983.
  • A medical history of asthma, angioedema hypertension, psychiatric illness, organ-system (cardiovascular, neurological, hepatic, hematopoietic, renal, pulmonary, endocrine, or gastrointestinal) disorders, ongoing infectious diseases, alcohol or drug abuse within 30 days prior to start of the study.
  • Blood chemistry (including alkaline phosphatase, glucose, ALt, AST, LDH, BUN, GGT, creatinine, bilirubin, electrolytes), hematology (including hemoglobin, hematocrit, red blood cell count, white blood cell count, differential, platelet count), and urinalysis values not within clinically acceptable limits upon evaluation by the investigator. The above tests will be performed within 30 days prior to the start of the study.
  • Evidence of usage of prescription drugs within 14 days, or OTC preparations (with the exception of acetaminophen, vitamins, medicated lozenges, dietary supplements and topical medications) within 7 days of the first drug administration, each period.
  • Alcohol consumption within 48 hours prior to drug administration until.
  • Known allergy to lisinopril or other ACE (angiotensin converting enzyme) inhibitors, such as captopril and enalapril, or to atropine.
  • Unacceptable electrocardiogram: sinus rhythm with evidence of AV block or ischemic changes.
  • Blood pressure and pulse rate outside of the following ranges: Systolic blood pressure (110-150 mmHg); Diastolic blood pressure (70-95 mmHg); Pulse (50-105 bpm).
  • Evidence of caffeine use within the last 48 hours, prior to dosing, or through the study up to and after the last blood collection, each period.
  • A positive HIV 1, hepatitis B surface antigen and urine screen for drugs of abuse within 30 days prior to the start of the study.
Male
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01375244
11506
No
Alfred Elvin/Director of Biopharmaceutics, Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc.
PharmaKinetics Laboratories, Inc.
Principal Investigator: Clifford L Ferguson, MD PharmaKinetics Laboratories, Inc.
Par Pharmaceutical, Inc.
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP